AbbVie Vyalev — Net revenues increased by 32.6% to $183.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 315.9%, from $44.00M to $183.00M. Over 2 years (FY 2023 to FY 2025), Vyalev — Net revenues shows an upward trend with a 1167.5% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates successful market penetration and growing physician adoption of the therapy, while a decrease may signal competitive pressure or challenges in patient access.
This metric represents the total gross sales of the Vyalev product line minus returns, allowances, and rebates. It serve...
Comparable to revenue metrics for specific high-growth pharmaceutical assets or newly launched specialty drugs at peer biopharmaceutical companies.
abbv_segment_vyalev_net_revenues| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $750.00K | $750.00K | $750.00K | $750.00K | $9.00M | $18.00M | $28.00M | $44.00M | $63.00M | $98.00M | $138.00M | $183.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | >999% | +100.0% | +55.6% | +57.1% | +43.2% | +55.6% | +40.8% | +32.6% |
| YoY Change | — | — | — | — | >999% | >999% | >999% | >999% | +600.0% | +444.4% | +392.9% | +315.9% |
We use cookies for analytics. See our Privacy and Cookie Policy.